A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorAstraZeneca
About this trial
The purpose of this study is to evaluate the safety and PK of AZD7760 when given as an intravenous (IV) infusion to healthy Japanese adult participants.
Eligibility criteria
Qualifiers
Body weight ≥ 45 kg and ≤ 110 kg and BMI within the range of ≥ 18.0 to ≤ 30.0 kg/m2 (inclusive) at screening.
Healthy Japanese participants with no clinically significant concomitant diseases or medications.
Disqualifiers
Known hypersensitivity to any component of the study intervention.
Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of mAbs.
Clinically significant bleeding disorder or prior history of significant bleeding or bruising following intramuscular injections or venipuncture.
AST or ALT above 1.5 × ULN at screening.
Trial design
Treatments tested in this trial
- AZD7760
- Placebo
Treatment groups
18 Participants
are divided into 3 treatment groupsLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Research Site Status unavailable 130-0004, Sumida-ku
Japan
JapanSponsors and collaborators
AstraZeneca
Lead sponsor
Parexel
Collaborator
Source ClinicalTrials.gov